{"id":"ocrelizumab-injection-ocrevus","safety":{"commonSideEffects":[{"rate":"approximately 35-40%","effect":"Infusion-related reactions"},{"rate":"approximately 25-30%","effect":"Upper respiratory tract infections"},{"rate":"approximately 10-15%","effect":"Lower respiratory tract infections"},{"rate":"approximately 10-15%","effect":"Headache"},{"rate":"approximately 10-15%","effect":"Nasopharyngitis"},{"rate":"low but serious","effect":"Immunosuppression / opportunistic infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ocrelizumab targets CD20, a surface antigen on B cells, leading to their selective depletion through antibody-dependent cellular cytotoxicity and direct induction of apoptosis. By reducing B cell populations, the drug decreases autoimmune attack on myelin and axons in the central nervous system. This mechanism reduces relapse rates and slows disability progression in multiple sclerosis.","oneSentence":"Ocrelizumab is a monoclonal antibody that depletes B cells by binding to CD20, reducing immune-mediated inflammation and demyelination.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:23:53.726Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing-remitting multiple sclerosis"},{"name":"Primary progressive multiple sclerosis"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ocrelizumab Injection [Ocrevus]","genericName":"Ocrelizumab Injection [Ocrevus]","companyName":"Fondation Ophtalmologique Adolphe de Rothschild","companyId":"fondation-ophtalmologique-adolphe-de-rothschild","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ocrelizumab Injection, also known as Ocrevus, is a binding agent that targets the B-lymphocyte antigen CD20. It works by binding to CD20, a protein found on the surface of B cells, which are a type of immune system cell.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}